Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin

Human Immunology

Volumn 72, Issue 6, 2011, Pages 463-469

  Basha, Saleem ^a   Hazenfeld, Staci ^a   Brady, Rebecca C ^a   Subbramanian, Ramu A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antigenic domains; Cellular immunity; ELISPOT; Influenza virus; Vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY RESPONSE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; INFLUENZA VIRUS A H3N2; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 79955753025     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.03.001     Document Type: Article

References (50)

1. Stohr K. Influenza-WHO cares. Lancet Infect Dis 2002, 2:517.
2. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999, 17(Suppl 1):S3-S10.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
4. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008, 320:340-346.
5. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., Miller M.A., et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005, 165:265-272.
6. Viboud C., Bjornstad O.N., Smith D.L., Simonsen L., Miller M.A., Grenfell B.T., et al. Synchrony, waves, and spatial hierarchies in the spread of influenza. Science 2006, 312:447-451.
7. Taubenberger J.K., Morens D.M. Influenza: The mother of all pandemics. Emerg Infect Dis 1918, 2006:15-22.
8. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-62.
9. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24:157-160.
10. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 1983, 37:529-549.
11. Ferguson N.M., Galvani A.P., Bush R.M. Ecological and immunological determinants of influenza evolution. Nature 2003, 422:428-433.
12. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305:371-376.
13. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31:417-427.
14. Gerhard W., Yewdell J., Frankel M.E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981, 290:713-717.
15. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289:373-378.
16. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990, 8:737-771.
17. Bentz J., Mittal A. Architecture of the influenza hemagglutinin membrane fusion site. Biochim Biophys Acta 2003, 1614:24-35.
18. Carrat F., Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
19. Hensley S.E., Das S.R., Bailey A.L., Schmidt L.M., Hickman H.D., Jayaraman A., et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009, 326:734-736.
20. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T-cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
21. Teijaro J.R., Verhoeven D., Page C.A., Turner D., Farber D.L. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 2010, 84:9217-9226.
22. Topham D.J., Doherty P.C. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol 1998, 72:882-885.
23. Patel A., Tran K., Gray M., Li Y., Yao X., et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27:3083-3089. Z.
24. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE;5:e9812.
25. Subbramanian R.A., Basha S., Brady R.C., Hazenfeld S., Shata M.T., Bernstein D.I., et al. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Hum Immunol 2010, 71:957-963.
26. Fanning T.G., Taubenberger J.K. Phylogenetically important regions of the influenza A H1 hemagglutinin protein. Virus Res 1999, 65:33-42.
27. Kiecker F., Streitz M., Ay B., Cherepnev G., Volk H.D., Volkmer-Engert R., et al. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose?. Hum Immunol 2004, 65:523-536.
28. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3:e2975.
29. He X.S., Holmes T.H., Zhang C., Mahmood K., Kemble G.W., Lewis D.B., et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80:11756-11766.
30. Reinhardt R.L., Liang H.E., Locksley R.M. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009, 10:385-393.
31. Zheng J., Liu Y., Lau Y.L., Tu W. CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4(+) regulatory T cells. Cell Mol Immunol 2010, 7:44-50.
32. Halloran M.E., Piedra P.A., Longini I.M., Gaglani M.J., Schmotzer B., Fewlass C., et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 2007, 25:4038-4045.
33. Belshe R.B., Ambrose C.S., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26(Suppl 4):D10-D16.
34. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
35. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
36. Wang Z., Tobler S., Roayaei J., Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009, 301:945-953.
37. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
38. Rhorer J., Ambrose C.S., Dickinson S., Hamilton H., Oleka N.A., Malinoski F.J., et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
39. Vesikari T. Emerging data on the safety and efficacy of influenza vaccines in children. Pediatr Infect Dis J 2008, 27:S159-S161.
40. Mendelman P.M., Rappaport R., Cho I., Block S., Gruber W., August M., et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 2004, 23:1053-1055.
41. Basta N.E., Halloran M.E., Matrajt L., Longini I.M. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol 2008, 168:1343-1352.
42. Sasaki S., Jaimes M.C., Holmes T.H., Dekker C.L., Mahmood K., Kemble G.W., et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81:215-228.
43. Brydak L.B., Tadeusz S., Magdalena M. Antibody response to influenza vaccination in healthy adults. Viral Immunol 2004, 17:609-615.
44. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26(SUPPL. 4):D5-D9.
45. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3:e1501.
46. Jeon S.H., Arnon R. Immunization with influenza virus hemagglutinin globular region containing the receptor-binding pocket. Viral Immunol 2002, 15:165-176.
47. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008, 3:e2517.
48. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
49. Gogolak P., Simon A., Horvath A., Rethi B., Simon I., Berkics K., et al. Mapping of a protective helper T-cell epitope of human influenza A virus hemagglutinin. Biochem Biophys Res Commun 2000, 270:190-198.
50. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial. JAMA 1999, 282:137-144.